
|Podcasts|October 31, 2018
On the Floor at the 2018 ESMO Congress
Author(s)Onclive Team
The 2018 ESMO Congress brought us all the way to Munich, Germany. At this annual congress, data across various tumor types were presented, including genitourinary malignancies, breast cancer, head and neck squamous cell carcinoma, melanoma, gastrointestinal malignancies, and lung cancer.
Advertisement
The 2018 ESMO Congress brought us all the way to Munich, Germany. At this annual congress, data across various tumor types were presented, including genitourinary malignancies, breast cancer, head and neck squamous cell carcinoma, melanoma, gastrointestinal malignancies, and lung cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































